Changes in body composition with ritonavir-boosted and unboosted atazanavir treatment in combination with Lamivudine and Stavudine: a 96-week randomized, controlled study.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 19302017.
- Also identified by DOI 10.1086/597776.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This 96-week, open-label, randomized study assessed changes in body composition in treatment-naive patients infected with human immunodeficiency virus type 1 who were treated with either atazanavir or ritonavir-boosted atazanavir, in combination with stavudine and lamivudine. Both treatment groups had similar increases in trunk fat, but patients treated with ritonavir-boosted atazanavir had a significantly lower incidence of lipoatrophy.
Medical subject headings
- Anti-HIV Agents
- Antiretroviral Therapy, Highly Active
- Body Composition
- HIV Infections
- Lamivudine
- Oligopeptides
- Pyridines
- Stavudine